ECOR is making progress in controlling the operational errors of the past management (CEO & other). However, there is still work to do in sorting out the strategic product development direction. Based upon experience with tissue stimulation, it is not clear that pursuing migraine & other headaches as a primary target will be the best use of ECOR technology. Using Class II stimulation technology for pain relief and related chronic conditions in home settings is most often a messy and lower margin business with low barriers to entry. Using stimulation to treat cute episodes of bronchoconstriction and similar clinical problems in hospital and first responder settings would address a smaller potential universe, but would be more readily adopted and at a greater price & margin point than pursuing gammaCore as a substitute for drugs in treating migraines.
Looking for Dan and his new team to address the above issue 'head on'. They've done a solid job of pulling the company out of a "tar pit" operationally and financially.
Some on this board are enamored with all the clinical situations in which gammaCore technology might be useful. Instead of pursuing multiple directions, ECOR needs to sift through the chaff and focus on a few profitable winners, hopefully in sufficiently large markets. If ECOR is successful with that approach, current investors will be rewarded if they have patience. Not so with early investors who got legally crammed down, though with a certain odor.
Market Data 
Markets 
AI
